These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal. Kleber M; Ihorst G; Udi J; Koch B; Wäsch R; Engelhardt M Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):38-48. PubMed ID: 22054851 [TBL] [Abstract][Full Text] [Related]
25. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. Warren KE; Goldman S; Pollack IF; Fangusaro J; Schaiquevich P; Stewart CF; Wallace D; Blaney SM; Packer R; Macdonald T; Jakacki R; Boyett JM; Kun LE J Clin Oncol; 2011 Jan; 29(3):324-9. PubMed ID: 21149652 [TBL] [Abstract][Full Text] [Related]
26. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Toumishey E; Prasad A; Dueck G; Chua N; Finch D; Johnston J; van der Jagt R; Stewart D; White D; Belch A; Reiman T Cancer; 2015 Mar; 121(5):716-23. PubMed ID: 25355245 [TBL] [Abstract][Full Text] [Related]
27. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD; N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762 [TBL] [Abstract][Full Text] [Related]
28. Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. Glaspy J; Atkins MB; Richards JM; Agarwala SS; O'Day S; Knight RD; Jungnelius JU; Bedikian AY Cancer; 2009 Nov; 115(22):5228-36. PubMed ID: 19728370 [TBL] [Abstract][Full Text] [Related]
29. Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma. Tufail M; Siegel DS; McBride L; Bilotti E; Bello E; Anand P; Olivo K; Bendarz U; McNeill A; Vesole DH Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):186-90. PubMed ID: 22381702 [TBL] [Abstract][Full Text] [Related]
30. Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. Bilen MA; Fu S; Falchook GS; Ng CS; Wheler JJ; Abdelrahim M; Erguvan-Dogan B; Hong DS; Tsimberidou AM; Kurzrock R; Naing A Cancer Chemother Pharmacol; 2015 Apr; 75(4):869-74. PubMed ID: 25666183 [TBL] [Abstract][Full Text] [Related]
31. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Dimopoulos MA; Christoulas D; Roussou M; Kastritis E; Migkou M; Gavriatopoulou M; Matsouka C; Mparmparoussi D; Psimenou E; Grapsa I; Efstathiou E; Terpos E Eur J Haematol; 2010 Jul; 85(1):1-5. PubMed ID: 20192988 [TBL] [Abstract][Full Text] [Related]
32. Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma. Reece DE; Masih-Khan E; Atenafu EG; Jimenez-Zepeda VH; Anglin P; Chen C; Kukreti V; Mikhael JR; Trudel S Br J Haematol; 2015 Jan; 168(1):46-54. PubMed ID: 25146584 [TBL] [Abstract][Full Text] [Related]
33. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide. Richardson P Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100 [TBL] [Abstract][Full Text] [Related]
34. Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. Dimopoulos MA; Tsatalas C; Zomas A; Hamilos G; Panayiotidis P; Margaritis D; Matsouka C; Economopoulos T; Anagnostopoulos N Semin Oncol; 2003 Apr; 30(2):265-9. PubMed ID: 12720150 [TBL] [Abstract][Full Text] [Related]
35. Lenalidomide: an update on evidence from clinical trials. Dimopoulos MA; Terpos E Blood Rev; 2010 Nov; 24 Suppl 1():S21-6. PubMed ID: 21126633 [TBL] [Abstract][Full Text] [Related]